Genomic and epigenomic analysis uncovers stemness features associated with worse survival in lethal prostate cancer, highlighting circulating biomarkers for therapy resistance.
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms remain ill-understood.
No takes yet. Share an insight, caveat, or question.
Chauhan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: